Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-trial access cohort bumetanide for developmental disorders
2020-002196-35Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bumetanide in Neurodevelopmental disorder (NDD), sponsored by Amsterdam University Medical Center. Primary endpoint: Patient-reported outcome measures. Started Nov 2020; status: active.
02
Drugs
bumetanide
03
Conditions
Neurodevelopmental disorder (NDD)
Beyond the preview
Go deeper on 2020-002196-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002196-35.